ClinicalTrials.gg
RecruitingNCT07113262Updated Nov 17, 2025

A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease

A Phase 3 interventional study of IBI311 and Placebo in Thyroid Eye Disease, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies in Graves Ophthalmopathy with a site in China — 25 open to participants now, 28 under way, 7 of them phase 3. Graves Ophthalmopathy · China.

Planned enrollment
11th of 45
111 · median 64
Started
2025
with 10 others
Phase 3
13 of 55
4 open now
Primary completion
2026-12
later than 6 of 27 live
Registered
39th of 55
by date
Lead sponsor
6 of 55
Innovent Biologics (Suzhou) Co. Ltd.

Among the 55 studies in Graves Ophthalmopathy with a site in China, this one is the 11th largest by planned enrollment of the 45 interventional ones that give a count, is one of 11 that started in 2025, is one of 13 in phase 3, reaches primary completion later than 6 of the 27 other live ones, and was the 39th registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

25 of the 55 studies in Graves Ophthalmopathy with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Graves Ophthalmopathy with a site in China, or all of them as a file.
02

Study summary

A multicenter clinical study to evaluate the efficacy and safety of IBI311 in subjects with inactive thyroid eye disease. The study consists of two parts, with a maximum duration of approximately 64 weeks.

Read the detailed description

This study is a multicenter, randomized, double-masked, placebo-controlled Phase III clinical study in inactive TED subjects. Approximately 111 eligible subjects will be randomly assigned to the IBI311 group and the placebo group in a 2:1 ratio on Day 1. The study consists of two parts, with a maximum duration of approximately 64 weeks. Part 1 includes a screening period and a double-masked treatment period, lasting for a total of approximately 28 weeks. Part 2 is a follow-up/open treatment period, lasting for up to approximately 36 weeks.

03

Conditions studied

  • Thyroid Eye Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.At screening and baseline, the following diagnostic criteria for inactive TED were met:

  1. CAS of both eyes ≤ 2 points during the screening period and baseline;
  2. According to the subject's medical history, CAS of both eyes ≤ 2 points at least 6 months before screening, or according to the subject's chief complaint or medical history, with all of the following characteristics: no progression of proptosis and no new diplopia caused by TED at least 6 months before screening or no progression of diplopia caused by TED and no new inflammatory TED symptoms;
  3. According to the subject's chief complaint or medical history, the first TED diagnosis before screening was ≥ 2 years and \< 10 years.

2.At baseline, the proptosis of the study eye was ≥20 mm. 3.If the subject is a female, she should be infertile or have a negative blood pregnancy test during the screening period and agree to take measures from the screening period to 120 days after the last medication. If the subject is a male, he should agree to take contraceptive measures from the screening period to 120 days after the last medication.

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following conditions will not be eligible to participate in this study:

  1. At baseline, the eyeball protrusion of the study eye decreased by ≥2 mm compared with the screening period;
  2. Subjects who have been previously diagnosed with DON, or who are determined by the investigator to have DON during screening (defined as: orbital MRI/CT showing orbital apex crowding or optic nerve compression, and at least 2 of the following ophthalmological examination abnormalities that cannot be explained by other reasons: ① best corrected visual acuity [BCVA] \< 0.8 or BCVA decreased by ≥ 2 lines compared with before the onset; ② abnormal pupillary light reflex or relative pupillary afferent disorder; ③ color vision abnormalities; ④ optic disc edema and optic disc pallor on fundus examination; ⑤ visual field loss; ⑥ visual evoked potential with prolonged latency and/or decreased amplitude);
  3. Patients with corneal ulcers that are judged by the researchers to have no relief after treatment;
  4. Planned to receive orbital radiotherapy or surgical treatment for TED (including orbital decompression, strabismus correction, eyelid correction, etc.) at any time before baseline or during the study period;
  5. Poorly controlled thyroid function, defined as free triiodothyronine (FT3) or free thyroxine (FT4) deviating from the normal reference value range of the local research center laboratory by more than 50% during screening;
  6. Any other diseases, metabolic disorders, abnormal physical examination or clinical laboratory test results, and there is reason to suspect that there may be diseases or conditions that may lead to to the use of the trial drug, affect the interpretation of the study results, or put the subjects at high risk of treatment complications, including but not limited to: confirmed or clinically suspected inflammatory bowel disease, coagulation disorders, history of acute cardiovascular and cerebrovascular diseases or treatment history within 180 days before screening(including but not limited to: cerebrovascular accident, , acute myocardial infarction, unstable angina, coronary artery bypass grafting, percutaneous coronary intervention [except diagnostic angiography], severe arrhythmia, etc.), history of malignant tumors treated or untreated in the past 5 years (except for skin squamous cell carcinoma, basal cell carcinoma, cervical carcinoma in situ, prostate carcinoma in situ or thyroid papillary carcinoma that have been successfully removed and have no evidence of ), severe systemic infection, proptosis not caused by TED, etc.;
  7. During the screening period, any ear has: tinnitus or other history of hearing loss; or abnormal pure tone audiometry results (defined as average bone conduction hearing threshold ≥25 dB at 0.5, 1, 2, 4 kHz or bone conduction hearing threshold ≥40 dB at any frequency);
  8. At screening, (AST) or alanine aminotransferase (ALT)>3×, or with active (defined as HBsAg positive with HBV-DNA load>1000 IU/mL), or receiving anti-hepatitis B virus treatment;
  9. At screening, (GFR) \<30 ml/min/1.73m2 (MDRD formula: GFR = 186 × serum creatinine (mg/dl) - 1.154 × (age) - 0.203 × (0.742 [if female]), serum creatinine unit conversion: 1 μmol/L = 0.0113 mg/dL);
  10. Poorly controlled diabetes at screening (defined as ≥8.0% at screening);
  11. At screening, patients have poorly controlled hypertension, with systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg; renal artery stenosis; or evidence of unstable blood pressure (including orthostatic hypotension, etc.);
  12. During screening, the 12-lead shows a heart rate of \<50 beats/min or >100 beats/min, the ECG indicates active heart disease, or the investigator believes that the ECG abnormality during screening will interfere with the interpretation of the ECG results during subsequent follow-up, especially excluding >500 ms;
  13. antibody or antibody positive or active syphilis (defined as non-specific syphilis antibody positive or requiring anti-syphilis treatment after consultation with the infectious disease department);
  14. Oral or intravenous within 30 days before screening;
  15. Use of glucocorticoid eye drops/eye ointment, or non-steroidal eye drops within 30 days before screening;
  16. Periorbital/periorbital injection of glucocorticoids within 90 days before screening;
  17. Any other non-steroidal immunosuppressants taken orally or intravenously within 90 days before screening;
  18. Received interleukin-6 receptor (IL-6R) antibody treatment within 180 days before screening;
  19. Received CD20 antibody treatment within 1 year before screening;
  20. Received IBI311 or TEPEZZA treatment at any time before screening;
  21. Have received any other TED treatment drugs under development at any time before screening (including but not limited to biological agents targeting IGF-1R, FcRn, and TSHR);
  22. Use of any other monoclonal antibody treatment within 90 days before screening;
  23. Participated in other interventional clinical trials within 90 days before screening (for drugs, within 5 half-lives, whichever is longer; excluding vitamins and minerals), or attempted to participate in other clinical trials during the study;
  24. Female subjects who are pregnant or lactating;
  25. Those who are known to be allergic to the study drug ingredients, or have a history of allergies to other monoclonal antibodies; Those who are considered by the researchers to be unsuitable for participating in this clinical trial due to other reasons.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
111 participants (estimated)

Study arms

  • Experimental
    Teprotumumab N01 injection (code name IBI311)

    Drug: IBI311

  • Placebo comparator
    placebo

    Drug: Placebo

Interventions

  • DrugIBI311

    Teprotumumab N01 injection (code name IBI311)

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Proptosis response rate of the study eye

    Proptosis response rate (i.e., percentage of participants with a ≥ 2 mm decrease from baseline in proptosis in the study eye and without a ≥ 2 mm increase of proptosis in the fellow eye) of the study eye at Week 24

    Time frame: 24 weeks

Secondary outcomes

  1. Change from baseline of proptosis in the study eye

    The Change from baseline of proptosis in the study eye at Week 24

    Time frame: 24 weeks

  2. Time to first achieve proptosis response in the study eye

    Time to first proptosis response in the study eye at Week 24.

    Time frame: 24 weeks

  3. Change from baseline in CAS in the study eye

    Change from baseline in CAS in the study eye at Week 24.

    Time frame: 24 weeks

  4. Diplopia responder rate

    Diplopia responder rate (percentage of subjects with ≥ 1-grade improvement in diplopia) at Week 24.

    Time frame: 24 weeks

  5. Proptosis response rate of the fellow eye

    Proptosis response rate of the fellow eye at week 24.

    Time frame: 24 weeks

  6. Change from baseline in the total score of the Graves' Ophthalmopathy Quality of Life (GO-QoL) questionnaire

    Change from baseline in the total score of the Graves' Ophthalmopathy Quality of Life (GO-QoL) questionnaire at week 24.

    Time frame: 24 weeks

  7. Evaluate the safety and tolerability of IBI311 in Part 1

    The number, incidence, severity, and relevance to study drugs or treatments of all ocular and other systemic AEs, TEAEs, AESIs, and SAEs.

    Time frame: up to 24 weeks

  8. Proptosis response rate of the study eye in subjects with delayed IBI311 treatment in Part 2.

    Proptosis response rate of the study eye in subjects with delayed IBI311 treatment (those who have received placebo in Part 1) in Part 2.

    Time frame: 48 weeks

  9. Proptosis response rate of the study eye in subjects with two consecutive circles of IBI311 treatment.

    Proptosis response rate of the study eye in subjects with two consecutive circles of IBI311 treatment (one circle of IBI311 treatment in Part 1 and then another circle of IBI311 treatment in Part 2

    Time frame: 48 weeks

  10. Rate of disease flare/deterioration

    Rate of disease flare/deterioration (The proptosis of either eye increased by ≥2 mm compared to week 24, and/or the CAS increased by ≥2 points compared to week 24 with a CAS ≥3 points) in subjects with IBI311 treatment in Part 1

    Time frame: 48 weeks

  11. Proptosis response rate of the study eye in subjects with disease flare/deterioration and receive another circle of IBI311 treatment in Part 2

    Proptosis response rate of the study eye in subjects with disease flare/deterioration after IBI311 treatment in Part 1 and then receive another circle of IBI311 treatment in Part 2.

    Time frame: 48 weeks

  12. Evaluate the safety and tolerability of IBI311 in Part 2

    The number, incidence, severity, and relevance to study drugs or treatments of all ocular and other systemic AEs, TEAEs, AESIs, and SAEs.

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of Medical University
    Shenyang, Liaoning 110801, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

Of 29 phase 3 interventional studies under Graves Ophthalmopathy, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 25. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2025
First posted
Aug 8, 2025
StartActual
Sep 10, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07113262
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Sep 10, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 17, 2025

Study contacts

juan chen
Contact
juan.chen01@innoventbio.com
021 3183 7200

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI311

Start the discussion